Scientists at the University of California, San Francisco have discovered a common genetic driver of aggressive meningioma, which can help clinicians detect this dangerous cancer earlier and find new treatments for these difficult-to-treat tumors. A research team led by Dr. David Raleigh found that increased gene activity called FOXM1 seems to be responsible for the aggressive growth, and these tumors frequently relapse.
To investigate the factors that may lead to aggressive meningioma, Raleigh’s team collected 280 human meningioma samples from 1990 to 2015. Using a range of techniques, including RNA sequencing and targeted gene expression profiling, the researchers searched for links between gene activity and protein production in these ເນື້ອງອກ and patients’ clinical outcomes. Finally, a gene called FOXM1 was found to be the core of the growth of invasive meningioma, and also an indicator of the subsequent adverse clinical outcomes, including death.
ນັກຄົ້ນຄວ້າຍັງໄດ້ຄົ້ນພົບການເຊື່ອມຕໍ່ໃຫມ່ລະຫວ່າງການຂະຫຍາຍຕົວຂອງເຍື່ອຫຸ້ມສະຫມອງທີ່ຮຸກຮານແລະການກະຕຸ້ນຂອງເສັ້ນທາງສັນຍານ intercellular, ທີ່ເອີ້ນວ່າ Wnt, ເຊິ່ງມັກຈະມີບົດບາດໃນການພັດທະນາ embryonic ແລະການສ້າງເນື້ອເຍື່ອ. ເນື່ອງຈາກທາດໂປຼຕີນທີ່ຜະລິດໂດຍ FOXM1 ສາມາດສົ່ງສັນຍານຕາມເສັ້ນທາງ Wnt, ຂໍ້ມູນໃຫມ່ຊີ້ໃຫ້ເຫັນວ່າການເຮັດວຽກຂອງການຮ່ວມມືຂອງ FOXM1 ແລະ Wnt pathway ອາດຈະນໍາໄປສູ່ການແຜ່ຂະຫຍາຍຂອງ meningiomas ຕໍ່ມາ. Hypermethylation ອາດຈະເປັນຜົນກະທົບຕໍ່ການສ້າງຕັ້ງຂອງ meningiomas ຮຸກຮານ.
Raleigh said that future work needs to find out which genes FOXM1 activates to drive meningioma growth, and block these targets with clinical therapies. It is hoped that there will be drugs to stop the pathogenesis of ເນື້ອງອກໃນສະ ໝອງ in this pathway as soon as possible and benefit the majority of cancer patients.
